Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other ...

Bio-Techne Corporation (NASDAQ:TECH) Q2 2020 Earnings Conference Call February 4, 2020 9:00 AM ET Company Participants David Clair - Senior Director, Corporate Development Charles Kummeth - President and CEO Jim Hippel - CFO Conference Call Participants Dan Arias - Stifel Catherine Schulte - Baird Jacob Johnson - Stephens John Leonard - Wells Fargo Patrick Donnelly - Citi Alex Nowak - Craig Hallum Partners Operator Good morning and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------|---------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | WHERE SCIENCE INTERSECTS INNOVATION | | | | | | | | | Corporate Presentation January 2020 | | | | | | | | | | | | | | | | | | | | | | | | | © 2020 Bio-Techne®. All rights reserved. SAFE HARBOR STATEMENT Cautionary Statements This presentation contains "forward-looking s ...

| --- | --- | --- | --- | --- | --- | --- | |-------|---------------|---------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | WHERE SCIENCE INTERSECTS INNOVATION | | | | | | | November 2019 | Corporate Presentation | | | | | | | | | | | | | © 2019 Bio-Techne®. All rights reserved. ANTIBODIES PROTEINS © 2019 Bio-Techne®. All rights reserved. 2 | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal executive offices) (Zip Code) (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Exchange Act: For the quarterly period ended September 30, 2019, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For t ...

Bio-Techne Corporation (NASDAQ:TECH) Q1 2020 Earnings Conference Call October 29, 2019 9:00 AM ET Company Participants David Clair - Senior Director, Corporate Development Charles Kummeth - President and CEO Jim Hippel - CFO Conference Call Participants Puneet Souda - SVB Leerink Catherine Schulte - Robert W. Baird Unidentified Analyst - Craig-Hallum Capital Group Paul Knight - Janney Montgomery Operator Good morning and welcome to the Bio-Techne Earnings Conference Call for the First Quarter of Fiscal Year ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of inco ...

Bio-Techne Corporation (NASDAQ:TECH) Q4 2019 Earnings Conference Call August 6, 2019 9:00 AM ET Company Participants Chuck Kummeth - CEO Jim Hippel - CFO Conference Call Participants Puneet Souda - SVB Leerink Catherine Schulte - Baird Dan Leonard - Deutsche Bank Patrick Donnelly - Goldman Sachs Alex Nowak - Craig-Hallum Capital Group Paul Knight - Janney Operator Good morning and welcome to the Bio-Techne Earnings Conference Call for the Fourth Quarter of Fiscal Year 2019. At this time, all participants ha ...

Click to edit Master title style biotechne® Corporate Presentation June 2019 Business Overview B U S I N E S S O V E R V I E W C O R P O R A T E Legacy Revenue At a Glance: | --- | --- | --- | |------------------------------------|-------|-------| | | | | | | | | | President and CEO: Chuck Kummeth | | | | Headquarters: Minneapolis, MN | 25% | | | Number of Employees: ~2,100 | | | | World Wide Presence: 35 Locations | | | | FY2018 Revenues: $643 million | | | | NASDAQ: TECH | 10% | | | Market Cap: ~$7B | | 6 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jur ...